Stoney off S/A news.
“
PDS Biotechnology (NASDAQ:PDSB) reportedupdated data from an ongoing phase 2 trial of PDS0101 in combination with chemoradiotherapy to treat patients with cervical cancer.
The company said 9 out of 9 patients treated with PDS0101 and standard-of-care chemoradiotherapy...